{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:25:27Z","timestamp":1793802327313,"version":"4.6.1"},"reference-count":0,"publisher":"Laeknabladid\/The Icelandic Medical Journal","issue":"07\/08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["lbl"],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a severe and progressive neurodegenerative disorder. We describe four cases of familial ALS based on SOD1 mutations who received intrathecal treatment with the antisense oligonucleotide tofersen at Landsp\u00edtali University Hospital Iceland. Since initiation of treatment, there has not been any significant deterioration, and three patients have shown signs of cinical improvement. The cerebrospinal fluid concentration of neurofilament light chain (Nf-L), a biomarker of neuronal axonal damage, has decreased to the reference range of healthy individuals. No serious side effects have been observed.<\/jats:p>","DOI":"10.17992\/lbl.2025.0708.848","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:55:11Z","timestamp":1751367311000},"page":"314-317","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of familial ALS with the drug tofersen"],"prefix":"10.17992","volume":"111","author":[{"name":"Department of Neurology, University Hospital of Iceland, Reykjavik, Iceland,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Thorarinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"University of Iceland, Faculty of Medicine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Halldorsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust","family":"Hilmarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur","family":"Sveinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7439","published-online":{"date-parts":[[2025,7,3]]},"container-title":["Laeknabladid"],"original-title":["Me\u00f0fer\u00f0 vi\u00f0 \u00e6ttl\u00e6gum  ALS-sj\u00fakd\u00f3mi me\u00f0 lyfinu tofersen"],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:26:49Z","timestamp":1793798809000},"score":1,"resource":{"primary":{"URL":"https:\/\/laeknabladid.is\/tolublod\/0708-tbl-111-arg-2025\/sjukratilfelli-medferd-vid-aettlaegum-als-sjukdomi-med-lyfinu-tofersen-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":0,"journal-issue":{"issue":"07\/08","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.17992\/lbl.2025.0708.848","relation":{},"ISSN":["0023-7213","1670-4959"],"issn-type":[{"value":"0023-7213","type":"print"},{"value":"1670-4959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}